Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05696665

Role of Saffron and Chamomile in the Management of Parkinson's Disease

Conditions: Parkinson Disease, Neurodegenerative Diseases

Sex: All
Ages: 40 Years – 85 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 120
Sponsor: Jinnah Postgraduate Medical Centre

Location: Pakistan

Summary

In multitudinous preclinical studies, Saffron and Chamomile are found effective in treating PD. They can mitigate the neurodegenerative progression of the disease by curtailing dopaminergic and neuronal loss and by inhibiting alpha-synuclein aggregation. They also possess antioxidant and anti-inflammatory activities. The synergism of both drugs can manage Parkinson's disease and related neurological disorders although, clinical trials are needed for further elaboration. Therefore, the purpose of the study is to evaluate the effects of Saffron and Chamomile and their active compounds in treating Parkinson's disease. This combination may change psychometric measures (MDS-Unified Parkinson's Disease Rating Scale), biomarkers (including Alpha-synuclein), and oxidative stress-related to Parkinson's disease. This combination along with conventional therapy might be beneficial in managing patients with Parkinson's disease

Eligibility Criteria

Inclusion Criteria:• All diagnosed patients aged 40-years and above of either sex will be includedDiagnosis will be based on the UK Parkinson Disease Society Brain Bank Clinical Diagnostic Criteria reported by neurophysicians.Exclusion Criteria:• Patients with atypical Parkinsonism will be excluded.Patients with uncontrolled comorbidities will also be excluded.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05696665). StuddyBuddy aggregates publicly available trial information.